Glucagon-like Peptide 1 (7-36 hide) Secretion in Response to Luminal Sucrose from the Upper and Lower Gut: A Study Using α-Glucosidase Inhibition (Acarbose)

References

• Nauck M A, Bartels E, Ørskov C, Ebert R, Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide 1 [7–36 amide] infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 1993; 76: 912–7
   PubMed Web of Science ®Google Scholar
• Nathan D M, Schreiber E, Fogel H, Mojsov S, Habener JF. Insulinotropic action of glucagonlike peptide-1-(7–37) in diabetic and nondiabetic subjects. Diabetes Care 1992; 15: 270–6
   PubMed Web of Science ®Google Scholar
• Nauck M A, Kleine N, Ørskov C, Holst J J, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous GLP-1 (7–36 amide) in type 2-diabetic patients. Diabetologia 1993; 36: 741–4
   PubMed Web of Science ®Google Scholar
• Ørskov C. Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia 1992; 35: 701–11
   PubMed Web of Science ®Google Scholar
• Creutzfeldt W, Nauck MA. Gut hormones and diabetes mellitus. Diabetesmetab Rev 1992; 8: 149–77
   PubMed Web of Science ®Google Scholar
• Kreymann B, Ghatei M A, Williams G, Bloom SR. Glucagonlike peptide 1 7–36: a physiological incretin in man. Lancet 1987; 2: 1300–4
   PubMed Web of Science ®Google Scholar
• Varndell I M, Bishop A E, Sikri K L, Uttenthal L O, Bloom S R, Polak JM. Localization of glucagon-like peptide (GLP) immunoreactants in human gut and pancreas using light and electron microscopic immunocytochemistry. J Histochem Cytochem 1985; 33: 1080–6
   PubMed Web of Science ®Google Scholar
• Eissele R, Goke R, Willemer S, Harthus H P, Vermeer H, Arnold R, et al. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest 1992; 22: 283–91
   PubMed Web of Science ®Google Scholar
• Gray GM. Carbohydrate digestion and absorption. Gastroenterology 1970; 58: 96–107
   PubMed Web of Science ®Google Scholar
• Brubaker PL. Regulation of intestinal proglucagon-derived peptide secretion by intestinal regulatory peptides. Endocrinology 1991; 128: 3175–82
   PubMed Web of Science ®Google Scholar
• Roberge J N, Brubaker PL. Secretion of proglucagon-derived peptides in response to intestinal luminal nutrients. Endocrinology 1991; 128: 3169–74
   PubMed Web of Science ®Google Scholar
• Caspary WF. Sucrose malabsorption in man after ingestion of α-glucosidase inhibitor. Lancet 1978; 2: 1231–3
   PubMedGoogle Scholar
• Uttenthal L O, Ukponmwan O O, Ghiglione M, Bloom SR. Acute and short term effects of intestinal α-glucosidase inhibition on gut hormone responses in man. Dig Dis Sci 1987; 32: 139–44
   PubMedGoogle Scholar
• Hayakawa T, Kondo T, Okumura N, Nagai K, Shibata T, Kitigawa M. Enteroglucagon release in disaccharide malabsorption induced by intestinal α-glucosidase inhibition. Am J Gastroenterol 1989; 84: 523–6
   PubMedGoogle Scholar
• Ørskov C, Holst J J, Knuhtsen S, Baldissera F G, Poulsen S S, Nielsen OV. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology 1986; 119: 1467–75
   PubMed Web of Science ®Google Scholar
• Qualmann C, Nauck M, Holst J J, Ørskov C, Creutzfeldt W. Geringfiigige insulinotrope Wirkung von exogenem und endogenem GLP-1 [7–36 Amid] bei basalen Plasmaglucosekon-zentrationen bei Stoffwechselgesunden (abstract). Diabetes Stoffw 1992; 1: 134, Suppl
   Google Scholar
• Lembcke B, Folsch U R, Caspary W F, Ebert R, Creutzfeldt W. Influence of metronidazole on the breath hydrogen response and symptoms in acarbose-induced malabsorption of sucrose. Digestion 1983; 25: 186–93
   Google Scholar
• Kuzio M, Dryburgh J R, Malloy K M, Brown JC. Radio-immunoassay for gastric inhibitory polypeptide. Gastroenterology 1974; 66: 357–64
   PubMed Web of Science ®Google Scholar
• Ørskov C, Holst JJ. Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2). Scand J Clin Lab Invest 1987; 47: 165–74
   PubMedGoogle Scholar
• Holst JJ. Evidence that peak II GLI or enteroglucagon is identical to the C-terminal sequence (residues 33–69) of glicentin. Biochem J 1982; 207: 381–8
   PubMed Web of Science ®Google Scholar
• Ebert R, Creutzfeldt W. Decreased GIP secretion through impairment of absorption. Front Horm Res 1980; 7: 191–201
   Google Scholar
• Fölsch U R, Ebert R, Creutzfeldt W. Response of serum levels of gastric inhibitory polypeptide and insulin to sucrose ingestion during long-term application of acarbose. Scand J Gastroenterol 1981; 16: 629–32
   PubMed Web of Science ®Google Scholar
• Fölsch U R, Lembcke B, Ebert R, Caspary W F, Creutzfeldt W. Effect of acarbose and fibre on glucose and hormone response to sucrose load or mixed meal. Proceedings of the First International Symposium Acarbose, Effects on Carbohydrate and Fat Metabolism., W Creutzfeldt. Excerpta Medica Congress Series, 1981; 594: 97–106
   Google Scholar
• Nakabayashi H, Nishizawa M, Takeda R, Niijima A. A novel role of truncated glucagon-like peptide-1 in the enteroinsular axis (EM) [abstract]. Diabetes 1992; 41: 101A, Suppl 1
   Google Scholar
• Sasaki H, Manaka H, Yamantani K, Tominaga M. GLP-1 secretion coupled with Ndglucose transporter from the isolated perfused canine ileum. Digestion 1993; 54: 365–7
   Google Scholar
• Qualmann C, Nauck M A, Holst J J, Ørskov C, Creutzfeldt W. Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7–36 amide] in the fasting state in healthy subjects. Acta Diabetol 1995; 32: 13–6
   PubMed Web of Science ®Google Scholar
• Goke R, Wagner B, Fehmann H C, Goke B. Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide 1 (6–36) amide on the rat pancreas. Res Exp Med 1993; 193: 97–103
   PubMedGoogle Scholar
• Hanefeld M, Fischer S, Schulze J, Spengler M, Wargenau M, Schollberg K, et al. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 1991; 14: 732–7
   PubMed Web of Science ®Google Scholar
• Hoffmann J. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. Diabetes Care 1994; 17: 561–6
   PubMed Web of Science ®Google Scholar